Drugs / BMS-188797
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00006086 | Jun 2000 → Feb 2003 | cancer of unknown primary site | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00005611 | — | cancer of unknown primary site | H. Lee Moffitt Cancer Center and Research Institute | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-188797 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005611 ↗ |
| Known as | 4-desacetylpaclitaxel 4-methyl carbonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096237 ↗ |
| Modality | Small molecule | “the taxane BMS-188797” PMID 16428495 ↗ Jan 2006 |
| Route | Intravenous | “Patients receive BMS-188797 IV over 1 hour.” NCT00005611 ↗ |